← Leaderboards
Niren Murthy
University Of Texas Hlth Science Center
$14,125,926
Attributed
$30,550,457
Total exposure
15
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$30,550,457 · 15
By mechanism
R01$22,757,539 · 8
UG3$2,344,724 · 1
UH3$1,596,053 · 1
R33$1,386,261 · 1
R21$1,267,708 · 3
U19$1,198,172 · 1
Top collaborators
- Lee W Riley11 shared
- Mark Myron Goodman8 shared
- William Robert Taylor8 shared
- Luke P. Lee6 shared
- Krystof S Bankiewicz5 shared
- Hye Young Lee5 shared
- Irina M Conboy4 shared
- Adam R. Abate3 shared
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Hye Young Lee$1,644,264
- Sarah Christine Hopp$2,544,441
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseInnovationTechnologyExperimental StudyIn VivoCellsDesignInfectionFamilyProteinsPreventDetectionTissuesClustered Regularly Interspaced Short Palindromic RepeatsToxic EffectBacteriaLeadGenesReagentBrainNanoparticleEscherichia ColiGenerationsFormulation
Grant awards (48)
Sorting and Sequencing Latent Reservoirs in HIV+ Opioid Users$1,557,466
R01 · FY2025 · DA
Gene editing in the brain with CRISPR-PEG$667,668
R01 · FY2025 · MH
In utero treatment of Dup15q syndrome via lipid nanoparticle based gene editing$654,339
R01 · FY2025 · NS
Research Project III: RNP-CRISPR to Treat Huntington's Disease$623,889
U19 · FY2025 · NS · contact PI
Sorting and Sequencing Latent Reservoirs in HIV+ Opioid Users$1,560,507
R01 · FY2024 · DA
Gene editing in the brain with CRISPR-PEG$671,929
R01 · FY2024 · MH
Research Project III: RNP-CRISPR to Treat Huntington's Disease$574,283
U19 · FY2024 · NS · contact PI
Sorting and Sequencing Latent Reservoirs in HIV+ Opioid Users$1,630,854
R01 · FY2023 · DA
Imaging bacterial infections with 2nd generation maltodextrins$664,310
R01 · FY2023 · EB
Gene editing in the brain with CRISPR-PEG$608,458
R01 · FY2023 · MH
Development of a Nanoparticle-Based Gene Editing Technology for Neurological Applications$1,096,057
UH3 · FY2022 · NS
Imaging bacterial infections with 2nd generation maltodextrins$667,650
R01 · FY2022 · EB
Gene editing in the brain with CRISPR-PEG$646,076
R01 · FY2022 · MH
Development of a nanoparticle-based gene editing technology for neurological applications$499,996
UH3 · FY2022 · NS
Development of a Nanoparticle-Based Gene Editing Technology for Neurological Applications$782,842
UG3 · FY2021 · NS
Gene editing in the brain with CRISPR-PEG$694,396
R01 · FY2021 · MH
Imaging bacterial infections with 2nd generation maltodextrins$667,778
R01 · FY2021 · EB
Development of a nanoparticle-based gene editing technology for neurological applications$782,572
UG3 · FY2020 · NS
Imaging bacterial infections with 2nd generation maltodextrins$710,274
R01 · FY2020 · EB
Treatment of Duchenne Muscular Dystrophy with Cas9 Protein Complexed to Gold Nanoparticles$353,250
R01 · FY2020 · EB
Consortium for drug-resistant Gram-negative pathogen detection$1,071,131
R01 · FY2019 · AI
Development of a nanoparticle-based gene editing technology for neurological applications$779,310
UG3 · FY2019 · NS
Maltose Targeted Antibiotics$462,087
R33 · FY2019 · AI · contact PI
Treatment of Duchenne Muscular Dystrophy with Cas9 Protein Complexed to Gold Nanoparticles$353,250
R01 · FY2019 · EB
Consortium for drug-resistant Gram-negative pathogen detection$1,106,988
R01 · FY2018 · AI
18F Conjugated Maltodextrins for the Detection of Medical Device Infections$597,089
R01 · FY2018 · EB
Maltose Targeted Antibiotics$462,087
R33 · FY2018 · AI · contact PI
Treatment of Duchenne Muscular Dystrophy with Cas9 Protein Complexed to Gold Nanoparticles$353,250
R01 · FY2018 · EB
Consortium for drug-resistant Gram-negative pathogen detection$1,185,876
R01 · FY2017 · AI
18F Conjugated Maltodextrins for the Detection of Medical Device Infections$597,089
R01 · FY2017 · EB
Maltose Targeted Antibiotics$462,087
R33 · FY2017 · AI · contact PI
Treatment of Duchenne Muscular Dystrophy with Cas9 Protein Complexed to Gold Nanoparticles$353,250
R01 · FY2017 · EB
Consortium for drug-resistant Gram-negative pathogen detection$1,118,080
R01 · FY2016 · AI
18F Conjugated Maltodextrins for the Detection of Medical Device Infections$597,089
R01 · FY2016 · EB
Maltose Targeted Antibiotics$209,372
R21 · FY2016 · AI · contact PI
Consortium for drug-resistant Gram-negative pathogen detection$59,660
R01 · FY2016 · AI
Consortium for drug-resistant Gram-negative pathogen detection$1,154,056
R01 · FY2015 · AI
18F Conjugated Maltodextrins for the Detection of Medical Device Infections$611,089
R01 · FY2015 · EB
Maltose Targeted Antibiotics$204,553
R21 · FY2015 · AI · contact PI
Plaque detection with the hydrocyanines$351,810
R01 · FY2013 · HL · contact PI
Maltodextrin based antibiotics$190,894
R21 · FY2013 · AI · contact PI
Plaque detection with the hydrocyanines$369,272
R01 · FY2012 · HL · contact PI
Maltodextrin based antibiotics$245,252
R21 · FY2012 · AI · contact PI
Plaque detection with the hydrocyanines$370,221
R01 · FY2011 · HL · contact PI
Plaque detection with the hydrocyanines$370,286
R01 · FY2010 · HL · contact PI
Plaque detection with the hydrocyanines$383,098
R01 · FY2009 · HL · contact PI
Polyketal nanoparticles: a new biomaterial for protein delivery$216,685
R21 · FY2007 · EB · contact PI
Polyketal nanoparticles: a new biomaterial for protein delivery$200,952
R21 · FY2006 · EB · contact PI